Anxiety and depression affect nearly one in five pregnant women and new mothers. About 6-8% of pregnant women receive SSRIs for treatment. Recent comments from a FDA expert panel have cast doubts on the safety of SSRIs, leading to criticism from various medical societies. Significant health risks associated with untreated depression have been emphasized, including suicide and low birth weight. Healthcare provider groups argue the FDA's claims misrepresent evidence and hinder care for patients, highlighting concerns regarding misinformation and its impact on treatment approaches.
"Untreated or undertreated depression during pregnancy carries health risks, such as suicide, preterm birth, preeclampsia, and low birth weight," the Society for Maternal-Fetal Medicine wrote in a statement late last month.
"As experts in high-risk pregnancies, the Society for Maternal-Fetal Medicine (SMFM) and its members are alarmed by the unsubstantiated and inaccurate claims made by FDA panelists concerning maternal depression and the use of SSRI antidepressants during pregnancy," according to the statement from SMFM.
Collection
[
|
...
]